Mainz Biomed N.V. (BST:4TO)
Germany · Delayed Price · Currency is EUR 6.64
-0.10 (-1.48%)
Inactive · Last trade price on Dec 5, 2024
Mainz Biomed Company Description
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States.
The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product.
The company was founded in 2008 and is based in Mainz, Germany.
Mainz Biomed N.V.
| Country | Netherlands |
| Founded | 2008 |
| Industry | In Vitro and In Vivo Diagnostic Substances |
| Employees | 71 |
| CEO | Guido Baechler |
Contact Details
Address: Robert Koch Strasse 50 Mainz, 55129 Germany | |
| Phone | 49 6131 554 2860 |
| Website | mainzbiomed.com |
Stock Details
| Ticker Symbol | 4TO |
| Exchange | Stuttgart Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Guido Baechler | Chief Executive Officer |
| William Caragol | Chief Financial Officer |
| Christopher Von Torne | Chief Operating Officer |